Literature DB >> 23152036

Pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of liver tumors predicts subsequent treatment response.

Xiaodong Wang1, Joseph P Erinjeri, Xiaoyu Jia, Mithat Gonen, Karen T Brown, Constantinos T Sofocleous, George I Getrajdman, Lynn A Brody, Raymond H Thornton, Majid Maybody, Ann M Covey, Robert H Siegelbaum, William Alago, Stephen B Solomon.   

Abstract

PURPOSE: To determine if the pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of hepatic tumors predicts modified Response Evaluation Criteria in Solid Tumors (mRECIST) response.
MATERIALS AND METHODS: This study was approved by the Institutional Review Board with a waiver of authorization. One hundred four liver tumors were embolized with spherical embolic agents (Embospheres, Bead Block, LC Bead) and polyvinyl alcohol. Noncontrast CT was performed immediately after embolization to assess contrast retention in the targeted tumors, and treatment response was assessed by mRECIST criteria on follow-up CT (average time 9.0 ± 7.7 weeks after embolization). Tumor contrast retention (TCR) was determined based on change in Hounsfield units (HUs) of the index tumors between the preprocedure and immediate postprocedure scans; vascular contrast retention (VCR) was rated; and defects in contrast retention (DCR) were also documented. The morphology of residual enhancing tumor on follow-up CT was described as partial, circumferential, or total. Association between TCR variables and tumor response were assessed using multivariate logistic regression.
RESULTS: Of 104 hepatic tumors, 51 (49%) tumors had complete response (CR) by mRECIST criteria; 23 (22.1%) had partial response (PR); 21 (20.2%) had stable disease (SD); and 9 (8.7%) had progressive disease (PD). By multivariate analysis, TCR, VCR, and tumor size are independent predictors of CR (p = 0.02, 0.05, and 0.005 respectively). In 75 tumors, DCR was found to be an independent predictor of failure to achieve complete response (p < 0.0001) by imaging criteria.
CONCLUSION: TCR, VCR, and DCR on immediate posttreatment CT are independent predictors of CR by mRECIST criteria.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152036      PMCID: PMC4394653          DOI: 10.1007/s00270-012-0506-x

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  24 in total

1.  Comparative in vitro evaluation of microspherical embolisation agents.

Authors:  Andrew L Lewis; Clementine Adams; Wendy Busby; Stephen A Jones; Laura C Wolfenden; Simon W Leppard; Rosemary R Palmer; Sharon Small
Journal:  J Mater Sci Mater Med       Date:  2006-12       Impact factor: 3.896

2.  Identifying feeding arteries during TACE of hepatic tumors: comparison of C-arm CT and digital subtraction angiography.

Authors:  Jin Iwazawa; Shoichi Ohue; Takashi Mitani; Hisashi Abe; Naoko Hashimoto; Masao Hamuro; Kenji Nakamura
Journal:  AJR Am J Roentgenol       Date:  2009-04       Impact factor: 3.959

3.  MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Authors:  Roman Kloeckner; Gerd Otto; Stefan Biesterfeld; Katja Oberholzer; Christoph Dueber; Michael B Pitton
Journal:  Cardiovasc Intervent Radiol       Date:  2009-10-22       Impact factor: 2.740

4.  Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).

Authors:  Renumathy Dhanasekaran; David A Kooby; Charles A Staley; John S Kauh; Vinit Khanna; Hyun S Kim
Journal:  J Surg Oncol       Date:  2010-05-01       Impact factor: 3.454

Review 5.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Particle embolization of recurrent hepatocellular carcinoma after hepatectomy.

Authors:  Anne M Covey; Mary A Maluccio; Johanna Schubert; Leah BenPorat; Lynn A Brody; Constantinos T Sofocleous; George I Getrajdman; Yuman Fong; Karen T Brown
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

7.  Utility of C-arm CT in patients with hepatocellular carcinoma undergoing transhepatic arterial chemoembolization.

Authors:  Alessia Tognolini; John D Louie; Gloria L Hwang; Lawrence V Hofmann; Daniel Y Sze; Nishita Kothary
Journal:  J Vasc Interv Radiol       Date:  2010-02-04       Impact factor: 3.464

8.  Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up.

Authors:  Guido Bonomo; Vittorio Pedicini; Lorenzo Monfardini; Paolo Della Vigna; Dario Poretti; Gianluigi Orgera; Franco Orsi
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-03       Impact factor: 2.740

9.  Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings.

Authors:  B I Choi; H C Kim; J K Han; J H Park; Y I Kim; S T Kim; H S Lee; C Y Kim; M C Han
Journal:  Radiology       Date:  1992-03       Impact factor: 11.105

Review 10.  Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations.

Authors:  Riccardo Lencioni; Thierry de Baere; Marta Burrel; James G Caridi; Johannes Lammer; Katerina Malagari; Robert C G Martin; Elizabeth O'Grady; Maria Isabel Real; Thomas J Vogl; Anthony Watkinson; Jean-Francois H Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2011-10-19       Impact factor: 2.740

View more
  11 in total

1.  Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response.

Authors:  F H Cornelis; A Borgheresi; E N Petre; E Santos; S B Solomon; K Brown
Journal:  Cardiovasc Intervent Radiol       Date:  2017-08-02       Impact factor: 2.740

Review 2.  Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.

Authors:  Lin Mu; Julius Chapiro; Jeremiah Stringam; Jean-François Geschwind
Journal:  Cancer J       Date:  2016 Nov/Dec       Impact factor: 3.360

Review 3.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

4.  Immediate Postablation 18F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases.

Authors:  Francois H Cornelis; Elena N Petre; Efsevia Vakiani; David Klimstra; Jeremy C Durack; Mithat Gonen; Joseph Osborne; Stephen B Solomon; Constantinos T Sofocleous
Journal:  J Nucl Med       Date:  2018-02-09       Impact factor: 10.057

Review 5.  Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Guorong Jia; Juno Van Valkenburgh; Austin Z Chen; Quan Chen; Jindian Li; Changjing Zuo; Kai Chen
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-08-17

6.  Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model.

Authors:  Andrew S Mikhail; William F Pritchard; Ayele H Negussie; Venkatesh P Krishnasamy; Daniel B Amchin; John G Thompson; Paul G Wakim; David Woods; Ivane Bakhutashvili; Juan A Esparza-Trujillo; John W Karanian; Sean L Willis; Andrew L Lewis; Elliot B Levy; Bradford J Wood
Journal:  Radiology       Date:  2018-08-14       Impact factor: 11.105

7.  A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study.

Authors:  Rafael Duran; Karun Sharma; Matthew R Dreher; Koorosh Ashrafi; Sahar Mirpour; MingDe Lin; Ruediger E Schernthaner; Todd R Schlachter; Vania Tacher; Andrew L Lewis; Sean Willis; Mark den Hartog; Alessandro Radaelli; Ayele H Negussie; Bradford J Wood; Jean-François H Geschwind
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

8.  Computed tomography and histopathological findings after embolization with inherently radiopaque 40μm-microspheres, standard 40μm-microspheres and iodized oil in a porcine liver model.

Authors:  Dominik F Vollherbst; Theresa Gockner; Thuy Do; Kerstin Holzer; Carolin Mogler; Paul Flechsig; Alexander Harms; Christopher L Schlett; Philippe L Pereira; Götz M Richter; Hans U Kauczor; Christof M Sommer
Journal:  PLoS One       Date:  2018-07-09       Impact factor: 3.240

9.  Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.

Authors:  Pierleone Lucatelli; Luca Ginnani Corradini; Gianluca De Rubeis; Bianca Rocco; Fabrizio Basilico; Alessandro Cannavale; Pier Giorgio Nardis; Mario Corona; Luca Saba; Carlo Catalano; Mario Bezzi
Journal:  Cardiovasc Intervent Radiol       Date:  2019-03-06       Impact factor: 2.740

10.  Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response.

Authors:  Jungang Hu; Majid Maybody; Guang Cao; Xiao Wang; Hui Chen; Xu Zhu; Renjie Yang; Xiaodong Wang
Journal:  Cancer Imaging       Date:  2016-10-03       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.